MX366906B - Purificacion de iduronato-2-sulfatasa. - Google Patents

Purificacion de iduronato-2-sulfatasa.

Info

Publication number
MX366906B
MX366906B MX2016001228A MX2016001228A MX366906B MX 366906 B MX366906 B MX 366906B MX 2016001228 A MX2016001228 A MX 2016001228A MX 2016001228 A MX2016001228 A MX 2016001228A MX 366906 B MX366906 B MX 366906B
Authority
MX
Mexico
Prior art keywords
sulfatase
purified recombinant
seq
iduronate
purification
Prior art date
Application number
MX2016001228A
Other languages
English (en)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX366906B publication Critical patent/MX366906B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a el uso de una composición que comprende iduronto-2- sulfatasa (I2S) recombinante purificada que tiene la secuencia de aminoácidos de la SEQ ID NO: 1, en la manufactura de un medicamento para el tratamiento del síndrome de Hunter, en donde la l2S recombinante purificada comprende por lo menos 70% de conservación del residuo cisteína que corresponde a Cys59 de la SEQ ID NO: 1 a Ca-formilglicina (FGly), en donde la l2S recombinante purificada contiene menos de 150 ng/mg de Proteína de Célula Huésped (HCP).
MX2016001228A 2012-06-29 2013-06-28 Purificacion de iduronato-2-sulfatasa. MX366906B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
MX366906B true MX366906B (es) 2019-07-30

Family

ID=49778401

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015000190A MX336715B (es) 2012-06-29 2013-06-28 Purificacion de iduronato-2-sulfatasa.
MX2019008914A MX393364B (es) 2012-06-29 2013-06-28 Purificacion de iduronato-2-sulfatasa
MX2016001228A MX366906B (es) 2012-06-29 2013-06-28 Purificacion de iduronato-2-sulfatasa.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2015000190A MX336715B (es) 2012-06-29 2013-06-28 Purificacion de iduronato-2-sulfatasa.
MX2019008914A MX393364B (es) 2012-06-29 2013-06-28 Purificacion de iduronato-2-sulfatasa

Country Status (39)

Country Link
US (7) US9051556B2 (es)
EP (2) EP2867245B1 (es)
JP (4) JP6171007B2 (es)
KR (5) KR101380740B1 (es)
CN (3) CN104583225A (es)
AR (1) AR091647A1 (es)
AU (3) AU2013282395C1 (es)
BR (1) BR112014032567B1 (es)
CA (2) CA2877517C (es)
CL (1) CL2014003567A1 (es)
CO (1) CO7240396A2 (es)
CR (1) CR20140588A (es)
CY (1) CY1121519T1 (es)
DK (1) DK2867245T3 (es)
DO (1) DOP2014000294A (es)
EA (2) EA202090044A1 (es)
ES (1) ES2689468T3 (es)
GT (1) GT201400303A (es)
HK (3) HK1209431A1 (es)
HR (1) HRP20181897T1 (es)
HU (1) HUE040769T2 (es)
IL (4) IL236315A (es)
LT (1) LT2867245T (es)
MX (3) MX336715B (es)
MY (3) MY192068A (es)
NZ (3) NZ733366A (es)
PE (1) PE20150720A1 (es)
PH (3) PH12014502871A1 (es)
PL (1) PL2867245T3 (es)
PT (1) PT2867245T (es)
RS (1) RS58005B1 (es)
SG (2) SG11201408761VA (es)
SI (1) SI2867245T1 (es)
SM (1) SMT201800612T1 (es)
TR (1) TR201815811T4 (es)
TW (2) TWI587869B (es)
UA (2) UA129561C2 (es)
WO (1) WO2014005014A2 (es)
ZA (2) ZA201409397B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CA3034589A1 (en) 2016-08-25 2018-03-01 Jcr Pharmaceuticals Co., Ltd. Method for producing antibody fusion protein
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
CA3127228A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
KR20230088811A (ko) * 2020-10-23 2023-06-20 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제의 제조 동안 총 시알산 함량(tsac)을 제어하는 방법
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP1179000A4 (en) 1999-02-26 2005-10-12 Millennium Pharm Inc DECISION PROTEINS AND THEIR USE
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
AU7099200A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
SI2325302T1 (sl) 2003-02-11 2016-05-31 Shire Human Genetic Therapies, Inc. Celice, ki soizražajo sulfatazo in c-formilglicin generirajoči encim ter postopki in uporabe le-teh
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
US20100190210A1 (en) 2006-03-20 2010-07-29 Medarex, Inc. Protein Purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
MX2010007846A (es) * 2008-01-18 2010-10-05 Biomarin Pharm Inc Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
NZ702801A (en) * 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012042857A1 (ja) 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
JP7594365B2 (ja) 2024-12-04
IL248727A0 (en) 2017-01-31
PE20150720A1 (es) 2015-05-16
US9492511B2 (en) 2016-11-15
CN107596358A (zh) 2018-01-19
AU2016200469A1 (en) 2016-02-18
JP6505629B2 (ja) 2019-04-24
PH12014502871B1 (en) 2015-02-23
CA2877517A1 (en) 2014-01-03
GT201400303A (es) 2017-08-31
IL236315A (en) 2016-11-30
KR20140004603A (ko) 2014-01-13
DK2867245T3 (en) 2018-11-26
SG10201703489VA (en) 2017-05-30
MY192068A (en) 2022-07-25
PH12020500027A1 (en) 2021-03-15
KR101380740B1 (ko) 2014-04-11
EA202090044A1 (ru) 2020-07-31
BR112014032567A2 (pt) 2017-08-01
MX2015000190A (es) 2015-04-08
TWI553120B (zh) 2016-10-11
CY1121519T1 (el) 2020-05-29
KR20140002451A (ko) 2014-01-08
US20140004096A1 (en) 2014-01-02
PT2867245T (pt) 2018-11-26
AU2013282395A1 (en) 2015-01-29
US20240401010A1 (en) 2024-12-05
WO2014005014A3 (en) 2014-02-27
US12359178B2 (en) 2025-07-15
CN107596357A (zh) 2018-01-19
KR20200143339A (ko) 2020-12-23
AR091647A1 (es) 2015-02-18
CO7240396A2 (es) 2015-04-17
EP2867245A2 (en) 2015-05-06
AU2018200230A1 (en) 2018-02-01
AU2013282395C1 (en) 2016-03-24
US20210317426A1 (en) 2021-10-14
NZ703093A (en) 2017-08-25
SG11201408761VA (en) 2015-01-29
NZ733366A (en) 2019-12-20
MX393364B (es) 2025-03-19
US20150313972A1 (en) 2015-11-05
AU2016200469B2 (en) 2017-10-12
DOP2014000294A (es) 2015-03-15
WO2014005014A2 (en) 2014-01-03
JP2016119911A (ja) 2016-07-07
IL287057A (en) 2021-12-01
US9051556B2 (en) 2015-06-09
EA034549B1 (ru) 2020-02-19
JP2018121645A (ja) 2018-08-09
LT2867245T (lt) 2018-11-12
UA121959C2 (uk) 2020-08-25
PH12015502408B1 (en) 2020-02-14
AU2018200230B2 (en) 2020-01-02
RS58005B1 (sr) 2019-02-28
PH12014502871A1 (en) 2015-02-23
SI2867245T1 (sl) 2018-12-31
CA3008945A1 (en) 2014-01-03
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
NZ743910A (en) 2019-12-20
BR112014032567B1 (pt) 2022-09-13
PL2867245T3 (pl) 2019-02-28
HK1209431A1 (en) 2016-04-01
US20170073652A1 (en) 2017-03-16
HK1249026A1 (zh) 2018-10-26
PH12015502408A1 (en) 2018-03-26
UA129561C2 (uk) 2025-06-04
MY157087A (en) 2016-04-19
EP2867245B1 (en) 2018-09-12
MX2019008914A (es) 2019-09-26
TW201410868A (zh) 2014-03-16
US20240043817A1 (en) 2024-02-08
TW201703794A (zh) 2017-02-01
IL261264A (en) 2018-10-31
JP6171007B2 (ja) 2017-07-26
CA2877517C (en) 2018-07-31
IL261264B (en) 2021-10-31
HRP20181897T1 (hr) 2019-01-11
IL236315A0 (en) 2015-02-26
JP2020105209A (ja) 2020-07-09
MY180287A (en) 2020-11-27
HK1249027A1 (zh) 2018-10-26
IL287057B1 (en) 2026-01-01
HUE040769T2 (hu) 2019-03-28
JP2015523072A (ja) 2015-08-13
MX336715B (es) 2016-01-28
US11530393B2 (en) 2022-12-20
TWI587869B (zh) 2017-06-21
EA201492177A1 (ru) 2015-06-30
CL2014003567A1 (es) 2015-04-24
US10344270B2 (en) 2019-07-09
SMT201800612T1 (it) 2019-01-11
US20190359958A1 (en) 2019-11-28
AU2013282395B2 (en) 2015-12-03
CN104583225A (zh) 2015-04-29
KR20190064542A (ko) 2019-06-10
ZA201409397B (en) 2019-10-30
ES2689468T3 (es) 2018-11-14
EP3441398A1 (en) 2019-02-13
KR20220002227A (ko) 2022-01-06
ZA201803289B (en) 2021-04-28
EP2867245A4 (en) 2016-03-09
TR201815811T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
NI201200013A (es) Composición de insulina de acción prolongada
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
CO6382125A2 (es) Inhibidores de proteína quinasa
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
IN2014KN01714A (es)
IN2014KN01716A (es)
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
AR093569A1 (es) Tensioactivos pulmonares reconstituidos
MX2014013091A (es) Composicion farmaceutica.
BR112012022209A2 (pt) composições farmacêuticas compreendendo monoterpenos
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
PH12015502100A1 (en) Reducing the risk of autoimmune disease
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии